A5142/PH III/LOPINAVIR/RITONAVIR+EFAVIR FOR INITIAL THERAPY OF HIV-1 INFECTION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是比较三个治疗组之间的病毒学失败时间：lopinavir/ritonavir加efavirenz，lopinavir/ritonavir加d4T缓释剂(或齐多夫定)加3TC，以及efavirenz加d4T缓释剂(或zidovudine)加3TC，并比较三个治疗组之间成对完成方案的时间：lopinavir/ritonavir加d4T缓释剂(或齐多夫定)加3TC，以及efavirenz加d4T缓释剂(或zidovudine)加3TC。方案的完成将被定义为病毒学失败或与毒性相关的初始随机治疗方案的任何组成部分的终止。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to compare the time to virologic failure pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC, and to compare the time to regimen completion pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen.